Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

Article summary

Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced incremental data and analyses from its ongoing Phase 1/2a clinical trial of [ 212 Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). These analyses were presented today in an oral presentation at the 2026 North American Neuroendocrine Tumors Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 5-7, 2026 in Las Vegas, Nevada.